Reaume, M. N., Fizazi, K., Bryce, A. H., Chowdhury, S., Ryan, C. J., Villanueva, N., Caffo, O., Chakmakjian, C. G., Ernst, D. S., Feyerabend, S., Font, A., Ganju, V., Kushnir, I., Hajdenberg, J., Madsen, C. V., Borrow, J., Ong, V., Ostler, P. J. (2026). Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with
                    <i>BRCA</i>
                    mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.46